Charles Schwab Investment Management Inc Aclaris Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $601 Billion
- Q3 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 241,956 shares of ACRS stock, worth $609,729. This represents 0.0% of its overall portfolio holdings.
Number of Shares
241,956
Previous 261,298
7.4%
Holding current value
$609,729
Previous $371,000
23.72%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding ACRS
# of Institutions
104Shares Held
81.7MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN14.3MShares$35.9 Million24.79% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$22.4 Million2.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.52MShares$16.4 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.28MShares$13.3 Million0.02% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.61MShares$11.6 Million0.59% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $168M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...